celiprolol has been researched along with Cardiomyopathies in 3 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 7.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| "In this study, the effect of celiprolol (beta-1-antagonist with beta-2-agonistic activity) on hemodynamic and electrocardiographic parameters of patients with congestive heart failure due to ischemic (iCMP) and non-ischemic (niCMP) origin should be evaluated." | 5.09 | Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy. ( Hennersdorf, MG; Perings, C; Vester, EG, 1999) |
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 3.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, Y | 1 |
| Ryoke, T | 1 |
| Tanaka, N | 1 |
| Ohkusa, T | 1 |
| Matsuzaki, M | 1 |
| Hennersdorf, MG | 1 |
| Perings, C | 1 |
| Vester, EG | 1 |
| Barrett, JA | 1 |
| Magistro, AM | 1 |
| Smith, RD | 1 |
| Pruss, TP | 1 |
| Wolf, PS | 1 |
1 trial available for celiprolol and Cardiomyopathies
| Article | Year |
|---|---|
Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiomyopathies; Ca | 1999 |
2 other studies available for celiprolol and Cardiomyopathies
| Article | Year |
|---|---|
Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Body Weight; C | 1998 |
Celiprolol, a compound which attenuates myocardial acidosis and improves regional segmental function following ischemia in dogs: a comparison with propranolol.
Topics: Acidosis; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Body Temperature; Cardiomyopathies; | 1989 |